Skip to main content

Table 1 Clinicopathological characteristics of the study populations

From: A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study

 

Training set

Validation set

P

N

mean ± SD

N

mean ± SD

%

%

Age

1718

49.81 ± 10.416

573

48.96 ± 10.386

0.090

BMI

1540

23.47 ± 3.184

508

23.32 ± 3.074

0.358

Location of Lesions

0.781

 UOQ

814

47.38

272

47.47

 

 UIQ

298

17.35

90

15.71

 

 LIQ

100

5.82

32

5.58

 

 LOQ

180

10.48

64

11.17

 

 Central

220

12.81

71

12.39

 

 N/A

106

6.17

44

7.68

 

T-Stage1

0.684

 T1

535

31.14

183

31.94

 

 T2

986

57.39

333

58.12

 

 T3

131

7.63

35

6.11

 

 T4

66

3.84

22

3.84

 

Local Infiltration

0.685

 Skin & Chest Wall

4

0.23

1

0.17

 

 Only Skin

53

3.08

20

3.49

 

 Only Chest Wall

9

0.52

1

0.17

 

 No

1652

96.16

551

96.16

 

N-Stagea

0.031

 N0

1122

65.31

412

71.90

 

 N1

399

23.22

110

19.20

 

 N2

133

7.74

32

5.58

 

 N3

64

3.73

19

3.32

 

Histology

0.161

 CIS-Mi

48

2.79

19

3.32

 

 IDC

1503

87.49

493

86.04

 

 ILC

50

2.91

27

4.71

 

 Othersb

117

6.81

34

5.93

 

ER

0.648

 Positive

1020

59.37

334

58.29

 

 Negative

698

40.63

239

41.71

 

PR

0.704

 Positive

1037

60.36

351

61.26

 

 Negative

681

39.64

222

38.74

 

HER2

0.122

 Positive

436

25.38

127

22.16

 

 Negative

1282

74.62

446

77.84

 
  1. aT-stage and N-stage were both clinical stage determined by clinical (physical examination or radiologic) measurements
  2. bOthers: tubular carcinoma, mucinous carcinoma, medullary carcinoma
  3. Abbreviations: BMI body mass index, LIQ lower-inner quadrant, LOQ lower-outer quadrant, UIQ upper-inner quadrant, UOQ upper-outer quadrant, N/A not available, CIS-Mi ductal/lobular carcinoma in situ and microinvasive carcinoma; IDC infiltrating ductal carcinoma, ILC infiltrating lobular carcinoma, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor-2
Back to article page

Diagnostic Pathology

ISSN: 1746-1596

Contact us